Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2019.08.019
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Elsevier BV

Related search

Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2018English

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

SKIN The Journal of Cutaneous Medicine
2019English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study

British Journal of Dermatology
DermatologyMedicine
2019English

Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

British Journal of Dermatology
DermatologyMedicine
2018English

Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2017English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy